Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma

TY - JOUR

T1 - Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma

AU - Sandoval-Sus, Jose D.

AU - Brahim, Amanda

AU - Khan, Alina

AU - Raphael, Barbara

AU - Ansari-Lari, Ali

AU - Ruiz, Marco

N1 - Jose D. Sandoval-Sus Amanda Brahim Alina Khan Barbara Raphael Ali Ansari-Lari Marco Ruiz Primary effusion lymphoma (PEL) is a rare and aggressive herpesvirus-8 (HHV-8) driven B cell non-Hodgkin's lymphoma (NHL) that is usually associated with human immunodeficiency virus (HIV) infection, and has a poor prognosis.

PY - 2019/5/1

Y1 - 2019/5/1

UR - https://link.springer.com/article/10.1007/s12185-019-02592-3

U2 - 10.1007/s12185-019-02592-3

DO - 10.1007/s12185-019-02592-3

M3 - Article

VL - 109

JO - International Journal of Hematology

JF - International Journal of Hematology

ER -